Synergistic interaction between platinum-based antitumor agents and demethylcantharidin

Cancer Letters

Volumn 223, Issue 2, 2005, Pages 227-237

  To, Kenneth K W ^a   Ho, Yee Ping ^a   Au Yeung, Steve C F ^b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cytotoxicity; Demethylcantharidin; Platinum antitumor agents; Protein phosphatase inhibitors; Synergy

Indexed keywords

CARBOPLATIN; CISPLATIN; NORCANTHARIDIN; OXALIPLATIN; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PLATINUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; INOCULATION; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PATHOLOGY; PRIORITY JOURNAL; TOXICITY; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BODY WEIGHT; CANTHARIDIN; CARBOPLATIN; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DRUG INTERACTIONS; HUMANS; LEUKEMIA; LIVER NEOPLASMS; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

MUS MUSCULUS;

EID: 19344366710     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.10.036     Document Type: Article

References (33)

1. G. Giaccone Clinical perspectives on platinum resistance Drugs 59 2000 9 17
2. Y.P. Ho, S.C.F. Au-Yeung, and K.K.W. To Platinum-based anticancer agents: innovative design strategies and biological perspectives Med. Res. Rev. 23 2003 633 655
3. T. Tashiro, Y. Kawada, and Y. Sakurai Antitumor activity of a new platinum complex, oxalate(trans-l-1,2-diaminocyclohexane)platinum (II), new experimental data Biomed. Pharmacother. 43 1989 251 260
4. O. Rixe, W. Ortuzar, and M. Alvarez Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel Biochem. Pharmacol. 52 1996 1855 1865
5. Y.P. Ho, K.K.W. To, S.C.F. Au-Yeung, X. Wang, G. Lin, and X. Han Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety J. Med. Chem. 44 2001 2065 2068
6. K.K.W. To, X. Wang, C.W. Yu, Y.P. Ho, and S.C.F. Au-Yeung Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin Bioorg. Med. Chem. 12 2004 4565 4573
7. Y.M. Li, and J.E. Casida Cantharidin-binding protein: identification as protein phosphatase 2A Proc. Natl Acad. Sci. USA 89 1992 11867 11870
8. 1, and 2B Bioorg. Med. Chem. Lett. 7 1997 1833 1836
9. G.S. Wang Medical uses of Mylabris in ancient China and recent studies J. Ethnopharmacol. 26 1989 147 162
10. D. Barford, A.K. Das, and M.P. Egloff The structure and mechanism of protein phosphatases: insights into catalysis and regulation Annu. Rev. Biophys. Biomol. Struct. 27 1998 133 164
11. P. Cohen The structure and regulation of protein phosphatases Annu. Rev. Biochem. 58 1989 453 508
12. S. Shenolinkar, and A.C. Nairn Protein phosphatases: recent progress Adv. Second Messenger Phosphoprotein Res. 23 1991 1 121
13. A. McCluskey, A.T.R. Sim, and J.A. Sakoff Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies J. Med. Chem. 45 2002 1151 1175
14. K.K.W. To, Y.P. Ho, and S.C.F. Au-Yeung Determination of the release of hydrolyzed demethylcantharidin from novel traditional Chinese medicine-platinum compounds with anticancer activity by gas chromatography J. Chromatogr. A 947 2002 319 326
15. R.R. Ariza, S.M. Keyse, J.G. Moggs, and R.D. Wood Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts Nucleic Acids Res. 24 1996 433 440
16. P. Engblom, V. Rantanen, J. Kulmala, H. Helenius, and S. Grenman Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines Br. J. Cancer 79 1999 286 292
17. S. Romanelli, P. Perego, G. Pratesi, N. Carenini, M. Tortoreto, and F. Zunino In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems Cancer Chemother. Pharmacol. 41 1998 385 390
18. L. Li, M.J. Keating, W. Plunkett, and L.Y. Yang Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance Mol. Pharmacol. 52 1997 798 806
19. T. Kogure, Y. Ueno, T. Iwasaki, and T. Shimosegawa The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors Cancer Chemother. Pharmacol. 53 2004 296 304
20. P. Frost, J.L. Abbruzzese, B. Hunt, D. Lee, and N. Ellis Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells Cancer Res. 50 1990 4572 4577
21. Y.J. Lidor, E.J. Shpall, W.P. Peters, and R.C. Bast Jr. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer Int. J. Cancer. 49 1991 704 710
22. T.C. Chou, and P. Talalay Quantitative analysis of dose effect relationship: the combined effects of multiple drugs on enzyme inhibitors G. Wever Advances in Enzyme Regulation 1984 Pergamon Press New York 27 55
23. T.C. Chou, and P. Talalay Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents K.R. Harrap T.A. Connors New Avenues in Developments Cancer Chemotherapy Bristol-Myers Symposium Series 1987 Academic Press New York 37 64
24. T.C. Chou, R.J. Motzer, Y. Tong, and G.J. Bosl Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J. Natl Cancer Inst. 86 1994 1517 1524
25. V.M. Richon, N. Schulte, and A. Eastman Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells Cancer Res. 47 1987 2056 2061
26. S.L. Lai, J. Hwang, R.P. Perng, and J. Whang-Peng Modulation of cisplatin resistance in acquired-resistant non-small cell lung cancer cells Oncol. Res. 7 1995 31 38
27. T. Mosmann Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
28. D.P. Houchens, and A.A. Ovejera Experimental therapy in subcutaneous transplants E. Boven B. Winograd The Nude Mice in Oncology Research 1991 CRC Press Boca Raton, FL 134 147
29. M. Matsumoto, Y. Takeda, H. Maki, K. Hojo, T. Wada, and Y. Nishitani Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer Jpn. J. Cancer Res. 92 2001 51 58
30. J.M. Barret, C. Etievant, and B.T. Hill In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloids, in combination with other anticancer drugs Cancer Chemother. Pharmacol. 45 2000 471 476
31. M.C. Strandberg, E. Bresnick, and A. Eastman The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells Chem. Biol. Interact. 39 1982 169 180
32. X.H. Liu, I. Balzsek, M. Comisso, S. Legras, S. Marion, and P. Quittet Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells Eur. J. Cancer 31 1995 953 963
33. M.C. Christian Carboplatin V. DeVita S. Hellman S.A. Rosenberg Cancer Principles and Practice of Oncology Update Series vol. 3 1989 Lippincott New York, NY 1 17